There is a common misconception that once AI becomes embedded in healthcare processes, it will take away human jobs. That scenario is unlikely to occur, however, because AI’s true role is to aggregate and analyze reams of data. That task is difficult for humans, so AI will be a welcome partner in clinical decision-making.
This stance is supported by Scott Gottlieb, former commissioner at the Food and Drug Administration (FDA) and now a board member at Pfizer and Illumina. He is also a senior fellow at the American Enterprise Institute, a public policy firm.
Gottlieb will headline the Artificial Intelligence in Healthcare and Diagnostics (AIHD) Conference on May 10-11 in San Jose, Calif., which is presented by the Precision Medicine Institute. The event will bring together executives from AI companies, hospitals, and diagnostics providers to discuss the state of artificial intelligence in healthcare and related business strategies.
AIHD’s speaker podium will also feature several other accomplished thought leaders in healthcare AI, including former HHS Deputy Chief of Staff Paul Mango, who was a key strategist for the White House’s Project Warp Speed, which focused on rapid development of COVID-19 vaccines.
“Once you can start to integrate clinical information with information from digital pathology, with information from sequencing, with information drawn from proteomic tests, you're going to be able develop a lot more insight into disease,” Gottlieb said during a 2021 webcast hosted by Proscia, an AI pathology software vendor.